An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
← catalyst calendarNCT06891287 · readout in 104 d
Sponsored by RANI Therapeutics (industry) · RANI — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-30 | actual | When the study began enrolling |
| Primary completion | 2026-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Combination product: RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity
- Drug: PG-102
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFTo evaluate safety and tolerability of RT-114 by assessing treatment emergent adverse events (TEAEs)
measured Single dose and 8 weeks of repeat dosing
Permalink · RANI's whole pipeline · Catalyst calendar · Every registered study · What changed